Description
The global blood and blood components market was valued at USD 14.1 billion in 2025 and is projected to reach USD 18.6 billion by 2032, expanding at 4% CAGR from 2026 to 2032. The market represents an essential component of modern healthcare systems, with demand driven by emergency blood transfusions, surgical procedures, trauma care, cancer treatment, obstetric care, and the management of chronic hematological disorders. Unlike conventional medical products, blood and its components are biological resources with highly time-sensitive supply characteristics, making donor availability, collection infrastructure, testing, processing, storage, and distribution critical to market performance. The increasing volume of surgeries globally remains a major demand driver, while the rising prevalence of chronic diseases, including cancer and blood disorders, continues to create recurring requirements for red blood cells, platelets, plasma, and other components. The market is increasingly shifting toward component-based transfusion therapy, where donated blood is separated into clinically targeted products. Red blood cells represent the largest component category because of their broad use across surgery, trauma, anemia, oncology, and hemoglobin disorders. Platelets remain strategically important despite their comparatively smaller market value because their short storage life creates significant inventory-management challenges. Plasma also plays a dual role in transfusion medicine and downstream fractionation, creating additional opportunities around plasma collection and processing. Blood donation campaigns conducted by national blood services, nonprofit organizations, and healthcare institutions are strengthening donor participation and supporting supply continuity.
The market’s future development will increasingly depend on improving the efficiency, safety, and resilience of the blood supply chain. Short shelf life remains a structural challenge, particularly for platelets, increasing the importance of demand forecasting, inventory optimization, cold-chain management, redistribution networks, and wastage reduction. Transfusion-transmitted infections remain another important concern, requiring continuous investment in donor screening, pathogen detection, quality assurance, and pathogen-reduction technologies. At the same time, technological advancement is creating opportunities for automation, digital donor-management platforms, improved component processing, traceability systems, and data-driven inventory management. Personalized and targeted therapies represent another emerging opportunity as transfusion practices become increasingly aligned with patient-specific clinical requirements. North America currently represents the largest regional market, supported by mature blood-collection networks, established transfusion infrastructure, high healthcare utilization, and sophisticated testing and processing capabilities. Europe remains another major market due to its established national blood services and aging population, while Asia Pacific is expected to be the fastest-growing region, supported by increasing surgical volumes, expanding healthcare infrastructure, improving blood-collection systems, and growing demand for transfusion services. Latin America and the Middle East & Africa offer longer-term opportunities as voluntary donation programs, component-processing capabilities, testing infrastructure, and healthcare access continue to develop. Overall, the market is shifting from a collection-focused model toward an integrated blood-management ecosystem in which donor recruitment, component utilization, digitalization, safety, supply-chain resilience, and efficient resource allocation increasingly determine market growth.
Key Highlights of the Report
• Blood components represent the leading product segment, reflecting the increasing adoption of component-based transfusion therapy and the ability to use a single donation for multiple clinical requirements.
• Whole blood remains clinically important, particularly for trauma resuscitation, emergency care, obstetric hemorrhage, military medicine, and healthcare settings with limited component-processing infrastructure.
• Red blood cells represent the largest blood-component category, supported by applications across surgery, trauma, anemia, cancer treatment, and chronic hematological conditions.
• Platelets remain a strategically important segment, particularly for oncology, transplantation, bleeding disorders, and other conditions requiring platelet support.
• Plasma has a dual clinical and industrial role, supporting transfusion therapy while also serving as an important input for plasma-derived medicinal products.
• White blood cells represent a specialized segment, with applications concentrated in specific clinical and therapeutic settings.
• Trauma and surgery represent the largest application segment, supported by the recurring need for blood products during major surgical procedures, trauma management, and hemorrhage control.
• Blood disorders constitute a significant demand segment, including anemia, hemophilia, von Willebrand disease, and other hematological conditions.
• Cancer treatment is an important source of recurring demand, particularly because chemotherapy, stem-cell transplantation, marrow suppression, and treatment-related bleeding can require transfusion support.
• Hospitals account for the dominant end-use demand, as they concentrate surgical, emergency, oncology, transfusion, and complex clinical services.
• Ambulatory surgical centers represent an emerging opportunity, particularly as selected procedures migrate toward outpatient care.
• Increasing surgical volumes globally remain a major growth driver, creating sustained demand for red blood cells, plasma, and platelets.
• The rising prevalence of chronic conditions, including cancer, supports recurring transfusion demand, particularly among patients requiring long-term or repeated clinical management.
• Blood donation campaigns are strengthening supply-side capacity, particularly when campaigns are combined with donor retention and repeat-donation programs.
• Growing adoption of plasma-based therapies is expanding blood-processing activity, although autologous platelet-rich plasma procedures should be distinguished from allogeneic blood-center demand.
• Short shelf life remains a fundamental market challenge, particularly for platelet products, increasing pressure on collection planning, inventory management, and distribution.
• Transfusion-transmitted infection remains a critical safety consideration, requiring continuous investment in donor screening, testing, pathogen reduction, and quality assurance.
• Personalized and targeted therapies create new opportunities, particularly through more precise component selection and patient-specific transfusion strategies.
• Digital solutions are becoming increasingly relevant, supporting donor recruitment, appointment management, inventory tracking, demand forecasting, traceability, and supply-chain coordination.
• Automation in blood processing is gaining importance, helping improve component consistency, operational efficiency, and traceability.
• Pathogen-reduction technologies offer an opportunity to improve blood-product safety, particularly for products with higher contamination risks.
• Inventory optimization represents an important growth opportunity, as blood services seek to reduce product wastage while maintaining adequate emergency reserves.
• North America remains the largest regional market, supported by advanced blood-collection systems, mature hospital infrastructure, and established transfusion services.
• Europe represents another major market, supported by national blood services, established donor networks, aging populations, and high healthcare utilization.
• Asia Pacific is the fastest-growing regional market, driven by expanding surgical capacity, rising chronic-disease burden, improving healthcare infrastructure, and strengthening blood-collection systems.
• Latin America offers growth opportunities through improved voluntary donation, modernization of blood services, and expansion of component-processing infrastructure.
• Middle East and Africa present significant unmet-demand opportunities, particularly where voluntary donation, testing coverage, component preparation, and transportation infrastructure remain underdeveloped.
• American Red Cross is identified as the market leader, with more than 12% market share in 2025.
• The top five players, including American Red Cross, NHS Blood and Transplant, Vitalant, OneBlood, and Canada Blood Services, collectively accounted for approximately 35% of the market in 2025.
Key Company Profiles
• AVIS
• Bloodworks Northwest
• ImpactLife
• Indian Red Cross Society
• Northern Ireland Blood Transfusion Service
• Scottish National Blood Transfusion Service
• Versiti
• Vitalant
• Welsh Blood Service
• NHS Blood and Transplant (NHSBT)
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
